secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001104659-23-089563
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma Q2 net loss $19.9M, cash $117.1M; dosed first patient in CT-0508+KEYTRUDA combo trial
--------------------------------------------------------------------------------

- Dosed first patient in Phase 1 trial of CT-0508 in combination with KEYTRUDA for HER2-overexpressing solid tumors.
- Nominated additional oncology target under Moderna collaboration; total of five nominated targets.
- Cash, cash equivalents and marketable securities $117.1M as of June 30, 2023 (down from $139.0M Q1 2023); expected to fund through end of 2024.
- Net loss $19.9M for Q2 2023 vs $14.8M for Q2 2022; R&D expenses increased to $18.5M from $14.2M.
- Appointed Eric Siegel as General Counsel and Terry Shields as SVP of Human Resources.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465923089563/0001104659-23-089563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465923089563/tm2322975d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-089563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer